Kailera's Tri-Agonist Shows Up to 16% Weight Loss in Phase 1
KLRA is trading near its 52-week low of $10.83 (3.4% above the low).
Summary
Kailera reported Phase 1 data for its tri-agonist KAI-4729, showing up to 16.0% mean weight loss at 12 mg over 12 weeks, along with a 67.3% reduction in liver fat. Ribupatide, its oral GLP-1, demonstrated 16.7% weight loss at 4 mg and similar exposure across injection sites. Safety was consistent with the GLP-1 class. This adds early clinical validation to the obesity pipeline, though the company's lead asset remains in Phase 3. A Phase 1 ex-China trial for KAI-4729 is planned for 2026, with data expected in 2027.
At the time of this announcement, KLRA was trading at $11.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $10.83 to $28.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.